GNMX News and Press, Aevi Genomic Medicine Inc.

Cerecor's (CERC) wholly-owned subsidiary, Aevi Genomic Medicine (GNMX) has entered into an expanded agreement with Kyowa Kirin (KYKOF), for exclusive worldwide rights to develop, manufacture and commercialize CERC-002 monoclonal antibody for all indications. Under the terms of agreement, Kyow...

-Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases  -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medical Officer ROCKVILLE, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceu...

GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that Sol Barer, PhD has been appointed as the Company&...

Merger activity increased with five new deals announced and five deals closing. Deal Statistics New Deals The acquisition of Audentes Therapeutics (BOLD) by Astellas Pharma (ALPMF) for $2.65 billion or $60.00 per share in cash. The acquisition of AK Steel Holding Corporation...

Aevi Genomic Medicine ( GNMX +7.3% ) to merge with Cerecor ( CERC -0.5% ) in an all-stock transaction valued at ~$16.1M, plus CVRs, for up to an additional $6.5M in subsequent milestone payments More news on: Aevi Genomic Medicine, Inc., Cerecor Inc., Healthcare stocks news, Mer...

-Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases -Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical Officer -Strategic Alternatives Being Explored for Neurological Assets and Millipred &#...

PHILADELPHIA , Oct. 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "the Company") today announced that the Nasdaq Hearings Panel has agreed to the transfer of the Company's shares to the Nasdaq Capital Market effective at the open of business on October 15, 2019 and...

PHILADELPHIA , Aug. 7, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced that it has obtained the right to exercise an exclusive global license for MEDI2338, a Phase 2-ready fully human monoclonal antibody (mAb) that targets interleukin 18 (IL-18). Th...

PHILADELPHIA , Aug. 6, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "the Company") today announced that Michael F. Cola , President and Chief Executive Officer, will present at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 1:20 p.m. E...

Nano cap Aevi Genomic Medicine (NASDAQ: GNMX ) is up  23%  after hours on the heels of its exclusive in-license agreement with Astellas Pharma ( OTCPK:ALPMF ) unit OSI Pharmaceuticals securing global development and commercialization rights to ASP7486 (formerly OSI-027). More n...